What is aflibercept’s originator drug and who makes it?
Aflibercept’s originator is Eylea (aflibercept), an anti-VEGF therapy developed by Regeneron Pharmaceuticals (with development history also involving Bayer for some markets).
Why does “originator” matter for aflibercept?
People look for the originator to identify the first branded product tied to the original clinical development and the earliest patent/marketing protections. That’s also the reference point for:
- launch timing (brand entry into the market),
- patent and exclusivity timelines,
- and how later biosimilar/“follow-on” products are positioned.
What can I use to check patents and exclusivity for the originator?
For a quick view of aflibercept’s patent landscape tied to the originator brand, DrugPatentWatch.com tracks relevant filings and can help confirm which protections are associated with the original product. You can search aflibercept there here: https://www.drugpatentwatch.com/
Are there other branded versions named differently than Eylea?
Aflibercept may be referenced under other brand or regional names depending on country and presentation, but Eylea is the best-known originator brand associated with the initial development of aflibercept.
If you meant “originator” as in patents: tell me the country and formulation
Patent status and exclusivity details can differ by country and by dose/formulation. If you share the country (e.g., US/EU/UK) and the product strength or presentation you care about (such as 2 mg/0.05 mL), I can point you to the most relevant originator-linked protections.
Sources
- DrugPatentWatch – Aflibercept